

PRESS RELEASE

31 March 2023 09:00:00 CEST

New number of shares and votes in Senzime AB (publ)

The number of shares and votes in Senzime AB (publ) ("Senzime") has during the month of March increased due to the rights issue that was resolved by the board of directors on 23 January 2023 and approved by an extraordinary general meeting of shareholders on 16 February 2023. In the rights issue, 12,682,675 new shares were issued.

As of 31 March 2023, the total number of shares in Senzime amounts to 82,566,660 (previously 69,883,985 shares), with one vote each. The share capital amounts to SEK 10,320,832.500 (previously SEK 8,735,498.125).

As of 31 March 2023, Senzime holds no treasury shares.

For further information, please contact:

Pia Renaudin, CEO of Senzime AB

Phone: +46 (0) 70 813 34 17, email: pia.renaudin@senzime.com

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.

This information is information that Senzime is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-03-31 09:00 CEST.

Attachments

[New number of shares and votes in Senzime AB \(publ\)](#)